SCHEDULE: Margaret Taggett Takes 6.6% Stake in Biora Therapeutics
Beneficial Ownership Report
Margaret Ellen Taggett has disclosed a 6.6% passive ownership stake in Biora Therapeutics, Inc., holding 297,000 shares of common stock.
Summary
- Margaret Ellen Taggett acquired 297,000 shares of Biora Therapeutics, Inc. common stock.
- This represents a 6.6% beneficial ownership stake in the company.
- The percentage is based on 4,522,702 outstanding shares as reported in Biora Therapeutics' most recent Form 10-Q filed on November 14, 2024.
- The acquisition is for passive investment purposes and not intended to change or influence control of the issuer.
Sentiment
Score: 6
Explanation: The filing indicates a significant passive investment by an individual, which can be interpreted as a vote of confidence in the company's long-term prospects, without implying any intent to influence control.
Positives
- A significant individual investor, Margaret Ellen Taggett, has acquired a 6.6% stake, which can be interpreted as a signal of confidence in Biora Therapeutics' long-term prospects.
Negatives
- No specific negative information about Biora Therapeutics' performance or outlook is disclosed in this filing.
Risks
- The shares were not acquired for the purpose of changing or influencing control of the issuer, indicating a passive investment strategy by the reporting person.
Future Outlook
This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Biora Therapeutics' future outlook.
Industry Context
This filing indicates an individual investor's significant passive stake in Biora Therapeutics, a biotechnology company. While not indicative of broader industry trends, it reflects individual investor interest in the sector.
Stakeholder Impact
- Shareholders: Provides increased transparency regarding significant ownership and may signal investor confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 2024-11-14 | Date of Biora Therapeutics' most recent Form 10-Q filing, which reported 4,522,702 outstanding shares. |
| 2025-04-07 | Date of event which required the filing of this statement (acquisition of over 5% beneficial ownership). |
| 2025-08-04 | Date the Schedule 13G statement was signed and filed. |
Keywords
Biora Therapeutics, Beneficial Ownership, Schedule 13G, Common Stock, Passive Investment, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.